肺结核
药物发现
结核分枝杆菌
大流行
医学
文艺复兴
药品
临床试验
重症监护医学
疾病
广泛耐药结核
药物开发
传染病(医学专业)
基岩
药理学
2019年冠状病毒病(COVID-19)
生物信息学
病理
历史
生物
艺术史
作者
Guilherme Fernandes,Andrew M. Thompson,Daniele Castagnolo,William A. Denny,Jean Leandro dos Santos
标识
DOI:10.1021/acs.jmedchem.2c00227
摘要
Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to the 1.8 million deaths caused by COVID-19. The World Health Organization has stated that new TB drugs must be developed to end this pandemic. After decades of neglect in this field, a renaissance era of TB drug discovery has arrived, in which many novel candidates have entered clinical trials. However, while hundreds of molecules are reported annually as promising anti-TB agents, very few successfully progress to clinical development. In this Perspective, we critically review those anti-TB compounds published in the last 6 years that demonstrate good in vivo efficacy against Mycobacterium tuberculosis. Additionally, we highlight the main challenges and strategies for developing new TB drugs and the current global pipeline of drug candidates in clinical studies to foment fresh research perspectives.
科研通智能强力驱动
Strongly Powered by AbleSci AI